Market Overview

Alnylam to Webcast Presentations at Upcoming September Investor Conferences


Pharmaceuticals, Inc.
(NASDAQ:ALNY), the leading RNAi therapeutics
company, announced today that management will present company overviews
at the following conferences:

  • 2018 Wells Fargo Securities Healthcare Conference on Wednesday,
    September 5, 2018 at 10:15 am ET at the Westin Copley Place in Boston
  • 16th Annual Morgan Stanley Global Healthcare Conference on
    Thursday, September 13, 2018 at 12:20 pm ET at the Grand Hyatt in New
    York City

A live audio webcast of each presentation will be available on the
Investors section of the Company's website,
A replay will be available on the Alnylam website within 48 hours after
each event.

About Alnylam Pharmaceuticals

Alnylam (NASDAQ:ALNY) is leading the translation of RNA interference
(RNAi) into a whole new class of innovative medicines with the potential
to improve the lives of people afflicted with rare genetic,
cardio-metabolic, and hepatic infectious diseases. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
severe and debilitating diseases. Founded in 2002, Alnylam is delivering
on a bold vision to turn scientific possibility into reality, with a
robust discovery platform. ONPATTRO, available in the U.S. for the
treatment of the polyneuropathy of hereditary transthyretin-mediated
(hATTR) amyloidosis in adults, is Alnylam's first U.S. FDA-approved RNAi
therapeutic. Alnylam has a deep pipeline of investigational medicines,
including three product candidates that are in late-stage development.
Looking forward, Alnylam will continue to execute on its "Alnylam 2020"
strategy of building a multi-product, commercial-stage biopharmaceutical
company with a sustainable pipeline of RNAi-based medicines to address
the needs of patients who have limited or inadequate treatment options.
Alnylam employs over 800 people worldwide and is headquartered
in Cambridge, MA. For more information about our people, science and
pipeline, please visit and
engage with us on Twitter at @Alnylam or
on LinkedIn.

View Comments and Join the Discussion!